Decoy Therapeutics Inc. (DCOY): Nasdaq/NYSE listing notice — Salarius amends merger fixing 14.1% legacy ownership; Nasdaq delisting risk from $2.5M equity shortfall

Decoy Therapeutics Inc.

Amendment eliminates cash-based exchange ratio adjustment; legacy Salarius stockholders retain 14.1%, Decoy holders 85.9% of combined company.
Nasdaq notified Salarius on March 26, 2025 it fails minimum $2.5M stockholders' equity for continued listing.
Company must submit a compliance plan by May 12, 2025; if accepted, Nasdaq may grant up to 180 days to regain compliance.
If plan rejected or compliance not regained, Nasdaq may delist; Salarius can request a hearing for up to 180 additional days.

item 1.01 item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Decoy Therapeutics Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

March 26, 2025, the Company received a letter (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on the financial statements contained in its Form 10-K for the year ended December 31, 2024, the Company no longer complies with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market (the “Equity Standard”). In addition, as of March 28, 2025, the Company does not meet the alternative compliance standards relating to

View on SEC.gov

6 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Decoy Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001615219-25-000040

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.